JP2024513244A5 - - Google Patents
Info
- Publication number
- JP2024513244A5 JP2024513244A5 JP2023561319A JP2023561319A JP2024513244A5 JP 2024513244 A5 JP2024513244 A5 JP 2024513244A5 JP 2023561319 A JP2023561319 A JP 2023561319A JP 2023561319 A JP2023561319 A JP 2023561319A JP 2024513244 A5 JP2024513244 A5 JP 2024513244A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- amino acid
- substitution
- acid position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171705P | 2021-04-07 | 2021-04-07 | |
| US63/171,705 | 2021-04-07 | ||
| PCT/US2022/023402 WO2022216653A1 (en) | 2021-04-07 | 2022-04-05 | Antigen-binding protein constructs and antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513244A JP2024513244A (ja) | 2024-03-22 |
| JP2024513244A5 true JP2024513244A5 (cg-RX-API-DMAC7.html) | 2025-04-15 |
Family
ID=81384769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561319A Pending JP2024513244A (ja) | 2021-04-07 | 2022-04-05 | 抗原結合タンパク質構築物および抗体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240158493A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4320157A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024513244A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230165792A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117083300A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022254042A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215265A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL306129A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011919A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022216653A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120035607A (zh) * | 2022-10-12 | 2025-05-23 | 神话治疗股份有限公司 | Lrrc-15结合蛋白构建体及其用途 |
| WO2026093513A1 (en) * | 2024-10-31 | 2026-05-07 | Sotio Biotech A.S. | Anti-lrrc15 antibodies and uses thereof |
| WO2026112478A1 (en) * | 2024-11-24 | 2026-05-28 | Mythic Therapeutics, Inc. | Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| MX2012002651A (es) | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| NZ602220A (en) * | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CA2871934C (en) * | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CA2979671C (en) * | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| EP3283103A4 (en) * | 2015-04-15 | 2018-12-05 | Medimmune, LLC | Methods for treating clostridium difficile infection and associated disease |
| EP3325516B1 (en) * | 2015-07-21 | 2021-12-15 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor xiia |
| EP3383909B1 (en) * | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| JP2019501124A (ja) * | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | 抗huLRRC15抗体薬物コンジュゲート及びその使用方法 |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| RS61659B1 (sr) | 2016-05-17 | 2021-04-29 | Abbvie Biotherapeutics Inc | Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu |
| US20200199247A1 (en) * | 2017-06-07 | 2020-06-25 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CN114786732A (zh) * | 2019-06-06 | 2022-07-22 | 神话治疗股份有限公司 | 抗原结合蛋白构建体及其用途 |
| US20220306751A1 (en) * | 2019-09-13 | 2022-09-29 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
-
2022
- 2022-04-05 AU AU2022254042A patent/AU2022254042A1/en active Pending
- 2022-04-05 JP JP2023561319A patent/JP2024513244A/ja active Pending
- 2022-04-05 CA CA3215265A patent/CA3215265A1/en active Pending
- 2022-04-05 US US18/281,367 patent/US20240158493A1/en active Pending
- 2022-04-05 IL IL306129A patent/IL306129A/en unknown
- 2022-04-05 KR KR1020237036033A patent/KR20230165792A/ko active Pending
- 2022-04-05 CN CN202280026995.1A patent/CN117083300A/zh active Pending
- 2022-04-05 EP EP22718517.0A patent/EP4320157A1/en active Pending
- 2022-04-05 WO PCT/US2022/023402 patent/WO2022216653A1/en not_active Ceased
- 2022-04-05 MX MX2023011919A patent/MX2023011919A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210386865A1 (en) | Method for selectively manufacturing antibody-drug conjugate | |
| JP2024505577A5 (cg-RX-API-DMAC7.html) | ||
| JP6310033B2 (ja) | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 | |
| JP2019214628A (ja) | セリンプロテアーゼ分子および療法 | |
| JP6534654B2 (ja) | Tm4sf1結合性タンパク質およびそれを使用する方法 | |
| Fabbrini et al. | Selective occlusion of tumor blood vessels by targeted delivery of an antibody‐photosensitizer conjugate | |
| US20180243435A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| RS63918B1 (sr) | Antitelo-lek konjugati i njihova upotreba u tretmanu kancera | |
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| CN107007840A (zh) | 抗‑cd19类美登素免疫缀合物抗体在治疗b‑细胞恶性肿瘤症状中的用途 | |
| JP2022543771A5 (cg-RX-API-DMAC7.html) | ||
| CN111315779A (zh) | 抗-cd3抗体及包含其的用于癌症治疗的药物组合物 | |
| CN112135843A (zh) | 抗sez6抗体药物缀合物和使用方法 | |
| CA3196218A1 (en) | Means and methods for producing antibody-linker conjugates | |
| AU2016378744A1 (en) | Novel anti-UPK1B antibodies and methods of use | |
| AU2017214685B2 (en) | EGFL6 specific monoclonal antibodies and methods of their use | |
| JP2022534808A5 (cg-RX-API-DMAC7.html) | ||
| JP2020501513A (ja) | 治療用多標的コンストラクトおよびその使用 | |
| Sun et al. | hIMB1636-MMAE, a novel TROP2-targeting antibody-drug conjugate exerting potent antitumor efficacy in pancreatic cancer | |
| AU2017261369A1 (en) | Novel anti-TNFRSF21 antibodies and methods of use | |
| CN110075315B (zh) | 一种抗体偶联物及其制备方法和应用 | |
| JP2024523290A5 (cg-RX-API-DMAC7.html) | ||
| JP2022551844A5 (cg-RX-API-DMAC7.html) | ||
| JP2025509338A (ja) | Ror1標的結合分子とその使用 | |
| JP2019536802A (ja) | 毛様体神経栄養因子受容体リガンド結合剤およびその使用方法 |